Shares in ADC Therapeutics fell sharply after the company said it had suspended a trial of Zynlonta in previously untreated diffuse large B-cell lymphoma (DLBCL) patients
Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an
The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleare
Roche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and a first look at the data suggests it is on track for approval in w
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.